Evidence map›Paper›PMID 41366425›Full record

ArticleCell communication and signaling : CCS2025

IL-1β-mediated suppression of CIITA attenuates IFN-γ-induced MHC-II expression on Fibroblasts.

Lujun Chen, Hongwei Jiang, Bo Tan, Renhao Geng, Junjun Chen, Shaoxian Wu, Zhang Fang, Yanyan Lang, Hui Ma, Xiao Zheng and 1 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lujun Chen *Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Hongwei Jiang *Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Bo Tan *Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Renhao GengDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Junjun ChenDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Shaoxian WuDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Zhang FangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Yanyan LangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Hui MaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
Xiao ZhengDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China. zhengxiao@suda.edu.cn.ORCID http://orcid.org/0000-0002-6163-7414
Jingting JiangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China. jiangjingting@suda.edu.cn.ORCID http://orcid.org/0000-0002-3128-9762

Funding

Changzhou Clinical Medical Center CZZX202201Changzhou Medical Center of Nanjing Medical University CZKYCMCC202301Changzhou Science and Technology Project (Applied Based Research) CJ20250116Changzhou Science and Technology Project (Applied Based Research) CZ20250020Changzhou Science and Technology Support Program CE20235057Jiangsu Provincial Medical Key Discipline YXZDXK202236Prospective Research Program of Changzhou Xitaihu Development Foundation For Frontier Cell-Therapeutic Technology 2022P010Prospective Research Program of Changzhou Xitaihu Development Foundation For Frontier Cell-Therapeutic Technology 2024P027Provincial-level Talent Program for National Center of Technology Innovation for Biopharmaceuticals NCTIB2024JS0101the Key R&D Project of Jiangsu Province BE2022719the Key R&D Project of Jiangsu Province BE2022721the Leading Talent of Changzhou"The 14th Five-Year Plan" High-Level Health Talents Training Project 2024CZLJ009the National Natural Science Foundation of China 32270955the National Natural Science Foundation of China 82473269
6 · The paper itself

Abstract

backgroundCancer-associated fibroblasts (CAFs) are key regulators in tumor microenvironment and tumor immunity, partly through MHC-II expression that modulates T-cell differentiation. However, the upstream cytokine signals controlling MHC-II expression in fibroblasts still remain poorly defined.

methodsWe examined MHC-II expression on fibroblasts under stimulation with interferon-γ (IFN-γ) and interleukin-1β (IL-1β) by using flow cytometry, transcriptomic analysis, and qRT-PCR. To dissect transcriptional regulation, we generated CIITA-overexpressing and CIITA-deficient fibroblast lines by lentiviral transduction and CRISPR/Cas9-mediated editing. Public scRNA-seq, ATAC-seq, and ChIP-seq datasets were further analyzed to validate molecular mechanisms.

resultsIFN-γ robustly up-regulated MHC-II expression on fibroblasts, while IL-1β selectively suppressed this induction without affecting PD-L1. Mechanistically, IL-1β attenuated IFN-γ-induced CIITA expression at the mRNA level but did not alter STAT1 abundance or phosphorylation. Functional assays confirmed that CIITA was indispensable for IFN-γ-driven MHC-II expression in fibroblasts. Integration of transcriptomic and epigenomic data demonstrated that CIITA directly bound MHC-II gene promoters and regulated chromatin accessibility.

conclusionsOur study identifies an IFN-γ/STAT1/CIITA axis as the central regulator of MHC-II expression in fibroblasts and reveals IL-1β as a potent suppressor of this pathway. These findings highlight a novel cytokine-mediated regulatory mechanism underlying CAF-driven immunosuppression within the tumor microenvironment.

Indexed as

FibroblastsHistocompatibility Antigens Class IIInterferon-gammaInterleukin-1betaNuclear ProteinsTrans-ActivatorsHumansSTAT1 Transcription FactorHistocompatibility Antigens Class IIInterferon-gammaInterleukin-1betaMHC class II transactivator proteinNuclear ProteinsSTAT1 Transcription FactorTrans-ActivatorsCIITAFibroblastsIFN-γIL-1βMHC-II

Identifiers

PMID41366425
PMCPMC12801534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.